Sufentanil

United States DSUVIA (sufentanil) Drug Insight and Market Forecasts, 2019-2022 and 2023-2032 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 14, 2023

The "United States DSUVIA Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States DSUVIA Drug Insight and Market Forecast - 2032" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about DSUVIA for acute pain in the United States.
  • A detailed picture of the DSUVIA for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the DSUVIA for acute pain.
  • This report provides a detailed market assessment of DSUVIA for acute pain in the United States.

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Acute Pain Market to Observe Growth at a CAGR of 8.3% During the Study Period (2019-2032), Assesses DelveInsight

Retrieved on: 
Thursday, January 26, 2023

LAS VEGAS, Jan. 26, 2023 /PRNewswire/ -- DelveInsight's Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • As per DelveInsight analysis, the acute pain market size in the US was approximately USD 3 billion in 2021.
  • According to the assessment done by DelveInsight, the estimated total acute pain cases in the US was approximately 100 million in 2021.
  • As per the DelveInsight estimates, in the US, in 2021, diagnosed incident cases of acute pain were approximately 94 million.
  • The acute pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022

Retrieved on: 
Thursday, November 3, 2022

HAYWARD, Calif., Nov. 3, 2022 /PRNewswire/ --AcelRx Pharmaceuticals, Inc.(Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close onMonday, November 14, 2022.

Key Points: 
  • HAYWARD, Calif., Nov. 3, 2022 /PRNewswire/ --AcelRx Pharmaceuticals, Inc.(Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company, today announced that it will release third quarter financial results after market close onMonday, November 14, 2022.
  • Thereafter, AcelRx management will host a live webcast and conference call at4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time onNovember 14, 2022,to discuss the financial results and provide an update on the Company's business.
  • The webcast can be accessed by visiting the "Investors" section of the Company's website at www.acelrx.com and clicking on the webcast link within the News & Events/Upcoming Events section.
  • The webcast will include a slide presentation and a replay will be available on the AcelRx website for 90 days following the event.

AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

Retrieved on: 
Monday, October 31, 2022

HAYWARD, Calif., Oct. 31, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract, entitled, "Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets" was presented on Friday, October 28th by Jeffrey DeWeese, M.D., FACS, at Plastic Surgery The Meeting 2022, held October 27-30, in Boston, MA. The study, conducted in 324 patients undergoing complex plastic surgery procedures, found many positive benefits of using sufentanil sublingual tablets (SST), 30 mcg (brand name DSUVIA®), including the ability to perform complex, extensive cosmetic procedures without general anesthesia, allowing a rapid discharge time.

Key Points: 
  • This "awake" surgery analysis was a prospective, single-group cohort that were 95% female and ranged in age from 15 to 81 years.
  • Procedures included liposuction, breast augmentation, breast reduction, brachioplasty, facelift, rhinoplasty, and blepharoplasty, and most significantly, abdominoplasty, which is usually only performed under general anesthesia.
  • A sufentanil sublingual tablet (SST) 30 mcg (DSUVIA) was administered sublingually, followed by injection of local and/or tumescent anesthesia.
  • DSUVIA allows an option for patients not wanting to undergo general anesthesia for both short and lengthy plastic surgery procedures."

AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant

Retrieved on: 
Thursday, October 27, 2022

HAYWARD, Calif., Oct. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that its commercial partner, Laboratorie Aguettant ("Aguettant"), has launched DZUVEO® (sufentanil sublingual tablet, 30 mcg), which is branded as DSUVIA® in the U.S., across Europe.

Key Points: 
  • "We remain impressed with, and are confident in the expertise of the Aguettant commercial team, and believe that the recent DSUVIA growth seen over the last five quarters here in the U.S. will support the Aguettant European launch."
  • "Partnering with AcelRx and leveraging the knowledge they've gained while commercializing DSUVIA in the U.S. has been extremely useful while we prepared for our launch across Europe," said Eric Rougemond, CEO of Aguettant.
  • DZUVEO has been approved by the European Medicines Agency and AcelRx's European commercialization partner, Aguettant, will market the drug in Europe.
  • Please refer to the Summary of Product Characteristics (SmPC) of DZUVEO in the European countries concerned by the marketing of this specialty product.

AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference

Retrieved on: 
Tuesday, September 6, 2022

The recorded presentation will also be available for 90 days on AcelRx's website within the Investors/News/Events section.

Key Points: 
  • The recorded presentation will also be available for 90 days on AcelRx's website within the Investors/News/Events section.
  • This release is intended for investors only.
  • For more information, including important safety information and black box warning for DSUVIA, please visit www.DSUVIA.com .
  • AcelRx Pharmaceuticals, Inc.is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.

AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022

Retrieved on: 
Thursday, August 11, 2022

The abstracts will be presented at the meeting and run from Thursday, October 27, 2022 at 1:30 pm until Sunday, October 30, 2022 at 4:30 pm ET.

Key Points: 
  • The abstracts will be presented at the meeting and run from Thursday, October 27, 2022 at 1:30 pm until Sunday, October 30, 2022 at 4:30 pm ET.
  • The time of the podium presentation is currently pending, but will be posted on the Investors/Events section of the AcelRx website once that information becomes available.
  • Plastic Surgery: The Meetingbrings together plastic surgeons from countries around the globe.
  • ASPS is the largest plastic surgery specialty organization in the world representing 94% of all board-certified plastic surgeons in the U.S. including more than 11,000 plastic surgeons worldwide.

AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting

Retrieved on: 
Wednesday, August 10, 2022

E-Abstracts will be presented virtually and made available to registrants throughout the entire meeting from Saturday, October 22 (7:00 a.m.

Key Points: 
  • E-Abstracts will be presented virtually and made available to registrants throughout the entire meeting from Saturday, October 22 (7:00 a.m.
  • The abstracts will remain available and open to meeting attendees for three months after the meeting.
  • The ANESTHESIOLOGY Annual Meeting is the marquee annual event for the American Society of Anesthesiologists.
  • AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.

AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022

Retrieved on: 
Thursday, July 28, 2022

HAYWARD, Calif., July 28, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.(Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close onThursday, August 11, 2022.

Key Points: 
  • HAYWARD, Calif., July 28, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.(Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close onThursday, August 11, 2022.
  • AcelRx management will host a live webcast and conference call at4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time onAugust 11, 2022to discuss the financial results and provide an update on the Company's business.
  • The webcast can be accessed by visiting the Investors section of the Company's website at www.acelrx.com and clicking on the webcast link on the Investors home page.
  • A webcast replay will be available on the AcelRx website for 90 days following the call and webcast.